Selected publications
-
Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia.
JAMA Dermatology.
2019
Academic Article
GET IT
Times cited: 2 -
Endocrine therapy-induced alopecia in patients with breast cancer.
JAMA Dermatology.
2018
Academic Article
GET IT
Times cited: 12 - A Pilot Study of Dose-Dense Paclitaxel with Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer. 2016 Academic Article GET IT
-
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Journal of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 49 -
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Breast Cancer Research.
2013
Academic Article
GET IT
Times cited: 54 -
High dose cytarabine and mitoxantrone: An effective induction regimen for high-risk Acute Myeloid Leukemia (AML).
Leukemia and Lymphoma.
2012
Academic Article
GET IT
Times cited: 11 -
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Breast Cancer Research and Treatment.
2012
Academic Article
GET IT
Times cited: 14 -
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Cancer.
2011
Academic Article
GET IT
Times cited: 14 -
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies.
Expert Review of Anticancer Therapy.
2011
Review
GET IT
Times cited: 216 -
Adjuvant taxanes: More to the story.
Clinical Breast Cancer.
2010
Review
GET IT
Times cited: 9 -
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Investigational New Drugs.
2008
Academic Article
GET IT
Times cited: 36 -
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
Molecular Cancer Therapeutics.
2002
Academic Article
GET IT
Times cited: 30